0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Statins Differentially Affect Amyloid Precursor Protein Metabolism in Presymptomatic PS1 and Non-PS1 Subjects FREE

Douglas A. Hinerfeld, PhD; Majaz Moonis, MD, MRCPI, DM; Joan M. Swearer, PhD; Stephen P. Baker, MScPH; Richard J. Caselli, MD; Ekaterina Rogaeva, PhD; Peter St. George-Hyslop, MD; Daniel A. Pollen, MD
Arch Neurol. 2007;64(11):1672-1673. doi:10.1001/archneur.64.11.1672.
Text Size: A A A
Published online

The putative potential of statins to retard the onset and progression of Alzheimer disease (AD) remains controversial.1,2 Statin therapy may have the potential to increase nonamyloidogenic soluble amyloid precursor protein α (sAPPα), thereby reducing β-amyloid 42 (Aβ42) and the downstream markers of neurodegeneration phospho-tau (p-tau) and total tau in the cerebrospinal fluid, and thus potentially slow the onset and progression of AD.35 Thus, in a small but unique cohort of cognitively normal subjects with presenilin 1 (PS1) mutations, we have taken the opportunity to conduct an hypothesis-generating pilot study to assess the effects of intensive statin therapy, using both a lipophilic (simvastatin) and a hydrophilic (atorvastatin) statin. We also studied a second group of subjects without such mutations but with hyperlipidemia (low-density lipoproteins [LDL]>100 mg/dL) and/or who are heterozygous for apolipoprotein ε4 (APOEε4).

Presymptomatic subjects with known PS1 mutations from 2 different kinships (Table) participated in these studies carried out under approval from an institutional review board. After they gave informed consent, subjects meeting the inclusion criteria (PS1 mutation, APOEε4, or APOEε3 with hyperlipidemia [LDL > 100 mg/dL]) were included. We performed sequential lumbar punctures as well as lipid profiles at baseline and at 6 and 12 months. Cerebrospinal fluid was immediately frozen at −80°C and so maintained prior to testing. Lumbar punctures at each visit were performed for each subject at a standard time of day to eliminate diurnal variability in any analyte. Athena Diagnostics (Worcester, Massachusetts) carried out the Innogenetics methods (Innogenetics, Ghent, Belgium) for determining levels of phospho-tau (hyperphorylated tau, eg, phosphorserine 181), total tau, and Aβ42. Concentrations of sAPPα, and sAPPβ were measured by enzyme-linked immunosorbent assay.6 All samples were analyzed together to avoid interrun variability. The study design allowed all subjects to act as their own controls. We used an intent-to-treat analysis assessing changes in analytes vs changes in serum lipid levels. Treatment outcomes were evaluated using general linear mixed models to estimate whether there had been a significant change in slope for values of analytes from prestatin levels to those at 6 and 12 months.

Table Graphic Jump LocationTable. Age, Sex, PS1 and APOE Genotypes, and Prestatin and Poststatin TC and LDL Levels for PS1 and Non-PS1 Subjects

All subjects showed profound decreases in both total cholesterol (P < .001) and LDL (P < .001) levels at 6 and 12 months after initiating statin therapy (Table). In PS1 subjects, statin therapy induced significant decreases of both sAPPα and sAPPβ. Combining results for both statins, sAPPα dropped by 16.5% (P = .001) and sAPPβ dropped by 21.2% (P < .001). When the effects were categorized according to drug type, simvastatin decreased sAPPα by −26.5% (P < .001) and sAPPβ by −31.5% (P < .001). There were no significant changes in the PS1 group treated with atorvastatin for either sAPPα or sAPPβ. Ratios of sAPPα to sAPPβ remained unchanged after treatment. Statin therapy reduced p-tau values in 5 of 6 PS1 subjects by −8.3% and approached significance (P = .08). There were no significant changes in total tau or Aβ42.

In the non-PS1 subjects and when controlling for reductions in total cholesterol, sAPPα was increased by 9.6% (P = .008) by atorvastatin and 23.7% (P < .001) by simvastatin. Increases in sAPPβ were not significant, but as with the PS1 group, sAPPα to sAPPβ ratios did not change after statin therapy. There were no significant changes in Aβ42, p-tau, and total tau.

These results are not easily interpretable based on the assumption that an increase in sAPPα occurs with a corresponding decrease in the available APP for cleavage by β-secretase. Instead, our results are more consistent with the interpretation that treatment increased either the production or the availability of the APP substrate in non-PS1 subjects and decreased either factor in subjects with PS1 mutations. It remains to be determined whether these differential effects are related to the lipid-lowering or pleiotropic effects of statins.

ARTICLE INFORMATION

Correspondence: Dr Majaz Moonis, Department of Neurology, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA 01655 (monism@ummhc.org).

Author Contributions:Study concept and design: Hinerfeld, Moonis, St. George-Hyslop, and Pollen. Acquisition of data: Hinerfeld, Moonis, Swearer, Caselli, Rogaeva, and Pollen. Analysis and interpretation of data: Hinerfeld, Moonis, Baker, St. George-Hyslop, and Pollen. Drafting of the manuscript: Hinerfeld, Moonis, Swearer, Baker, St. George-Hyslop, and Pollen. Critical revision of the manuscript for important intellectual content: Hinerfeld, Moonis, Baker, Caselli, Rogaeva, St. George-Hyslop, and Pollen. Statistical analysis: Baker. Obtained funding: Moonis and Pollen. Administrative, technical, and material support: Hinerfeld, Moonis, Swearer, Caselli, and Pollen. Study supervision: Hinerfeld, Moonis, and Pollen.

Financial Disclosure: None reported.

Funding/Support: This study was supported by a gift from the Edith Marrone Memorial Foundation and from an anonymous donor.

Additional Information: Drs Pollen and Swearer are in the Department of Neurology, University of Massachusetts Medical School, Worcester. Mr Baker is in the Bioinformatics Unit, Information Service and Department of Cell Biology, University of Massachusetts Medical School. Dr Hinerfeld worked on the project while at the University of Massachusetts but has since moved to the Jackson Laboratory, Bar Harbor, Maine. Drs Hyslop and Rogaeva are in the Division of Neurology, Department of Medicine, University of Toronto and Toronto Western Hospital, Toronto, Ontario, Canada. Dr Caselli is in the Department of Neurology, Mayo Clinic, Scottsdale, Arizona.

Sparks  DLSabbagh  MNConnor  DJ  et al.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62 (5) 753- 757
PubMed Link to Article
Jick  HZornberg  GLJick  SS  et al.  Statins and the risk of dementia. Lancet 2000;356 (9242) 1627- 1631
PubMed Link to Article
Simons  MKeller  PDeStrooper  B  et al.  Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998;95 (11) 6460- 6465
PubMed Link to Article
Kojro  EGimpi  GLammich  S  et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 2001;98 (10) 5815- 5820
PubMed Link to Article
Parvathy  SEhrlich  MPedrini  S  et al.  Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neurochem 2004;90 (4) 1005- 1010
PubMed Link to Article
Johnson-Wood  KLee  MMotter  R  et al.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 1997;94 (4) 1550- 1555
PubMed Link to Article

Figures

Tables

Table Graphic Jump LocationTable. Age, Sex, PS1 and APOE Genotypes, and Prestatin and Poststatin TC and LDL Levels for PS1 and Non-PS1 Subjects

References

Sparks  DLSabbagh  MNConnor  DJ  et al.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62 (5) 753- 757
PubMed Link to Article
Jick  HZornberg  GLJick  SS  et al.  Statins and the risk of dementia. Lancet 2000;356 (9242) 1627- 1631
PubMed Link to Article
Simons  MKeller  PDeStrooper  B  et al.  Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998;95 (11) 6460- 6465
PubMed Link to Article
Kojro  EGimpi  GLammich  S  et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 2001;98 (10) 5815- 5820
PubMed Link to Article
Parvathy  SEhrlich  MPedrini  S  et al.  Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neurochem 2004;90 (4) 1005- 1010
PubMed Link to Article
Johnson-Wood  KLee  MMotter  R  et al.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 1997;94 (4) 1550- 1555
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

635 Views
8 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
The Biological Agent

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Is There Potentially Compelling Evidence for a Class Effect?